Basal cell carcinoma or BCC is the most common cancer worldwide. But up to 1% of these cancers become locally advanced. Locally advanced basal cell carcinomas or laBCCs are much harder to treat through conventional treatment methods. ODOMZO® (sonidegib) is a prescription medicine used to treat adults with basal cell carcinoma that has come back following surgery or radiation or that cannot be treated with surgery or radiation. ODOMZO is currently the only hedgehog pathway inhibitor (HHI) proven to provide more than 2 years of tumor response in laBCC patients. Watch as Dr. Aaron Farberg and his laBCC patient Kara explore this treatment option.
Choose Health
Stronger Together – American Society for Clinical Pathology
The American Society for Clinical Pathology (ASCP) mission is to provide excellence in education, certification, and advocacy on behalf of patients, pathologists, and laboratory professionals. It continually pushes forward to better understand how they can share their knowledge with the healthcare community to provide high-quality care for all.
